Farmakogenetik – MIS-lab

Publikationer

Utvalda publikationer

• Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2024;90(3):740-747

  Evidence for solanidine as a dietary CYP2D6 biomarker: Significant correlation with risperidone metabolism

  Wollmann BM; Smith RL; Kringen MK; Ingelman-Sundberg M; Molden E; Storset E
• Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2023;114(3):673-685

  Mechanistic, Functional, and Clinical Aspects of Pro-inflammatory Cytokine Mediated Regulation of ADME Gene Expression in 3D Human Liver Spheroids

  Kloditz K; Tewolde E; Nordling A; Ingelman-Sundberg M
• Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2023;113(6):1284-1294

  3D Spheroid Primary Human Hepatocytes for Prediction of Cytochrome P450 and Drug Transporter Induction

  Jarvinen E; Hammer HS; Poetz O; Ingelman-Sundberg M; Stage TB
• Article: NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY. 2023;49(1):e12867

  The humanised CYP2C19 transgenic mouse exhibits cerebellar atrophy and movement impairment reminiscent of ataxia

  Milosavljevic F; Brusini I; Atanasov A; Manojlovic M; Vucic M; Orescanin-Dusic Z; Brkljacic J; Miljevic C; Nikolic-Kokic A; Blagojevic D; Wang C; Damberg P; Pesic V; Tyndale RF; Ingelman-Sundberg M; Jukic MM
• Article: CELLS. 2023;12(2):302

  The Role of CTGF in Liver Fibrosis Induced in 3D Human Liver Spheroids

  Trampuz SR; van Riet S; Nordling A; Ingelman-Sundberg M
• Article: CTS-CLINICAL AND TRANSLATIONAL SCIENCE. 2023;16(1):62-72

  Impact of NFIB and CYP1A variants on clozapine serum concentration-A retrospective naturalistic cohort study on 526 patients with known smoking habits

  Lenk HC; Lovsletten Smith R; O'Connell KS; Jukic MM; Kringen MK; Andreassen OA; Ingelman-Sundberg M; Molden E
• Editorial comment: TRENDS IN PHARMACOLOGICAL SCIENCES. 2022;43(12):987-993

  Bridging the gap in neuropsychiatric translational research

  Ingelman-Sundberg M; Cadet JL; Gobbi G; Olson DE; Yohn S; Foster DJ
• Review: TRENDS IN PHARMACOLOGICAL SCIENCES. 2022;43(12):1055-1069

  Pharmacogenomics in treatment of depression and psychosis: an update

  Jukic M; Milosavljevi F; Molden E; Ingelman-Sundberg M
• Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2022;112(5):1000-1003

  Liquid Biopsies or Therapeutic Drug Monitoring for CYP Activity Profile Determination

  Pridgeon CS; Johansson I; Ingelman-Sundberg M
• Article: CTS-CLINICAL AND TRANSLATIONAL SCIENCE. 2022;15(9):2135-2145

  Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population

  Braten LS; Ingelman-Sundberg M; Jukic MM; Molden E; Kringen MK
• Article: PHARMACOGENOMICS JOURNAL. 2022;22(4):247-249

  The clinically relevant CYP2C8*3 and CYP2C9*2 haplotype is inherited from Neandertals

  Haeggstrom S; Ingelman-Sundberg M; Paabo S; Zeberg H
• Article: CELLS. 2022;11(10):1597

  Hepatocyte Thorns, A Novel Drug-Induced Stress Response in Human and Mouse Liver Spheroids

  Pridgeon CS; Bolhuis DP; Milosavljevic F; Manojlovic M; Vegvari A; Gaetani M; Jukic MM; Ingelman-Sundberg M
• Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2022;111(5):1165-1174

  The Polymorphic Nuclear Factor NFIB Regulates Hepatic CYP2D6 Expression and Influences Risperidone Metabolism in Psychiatric Patients

  Lenk HC; Kloditz K; Johansson I; Smith RL; Jukic M; Molden E; Ingelman-Sundberg M
• Article: ADVANCES IN PHARMACOLOGY. 2022;95:393-416

  Cytochrome P450 polymorphism: From evolution to clinical use.

  Ingelman-Sundberg M
• Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2021;110(3):750-758

  Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 Substrates

  Jukic MM; Smith RL; Molden E; Ingelman-Sundberg M
• Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2021;110(3):786-793

  A Novel CYP2C-Haplotype Associated With Ultrarapid Metabolism of Escitalopram

  Braten LS; Haslemo T; Jukic MM; Ivanov M; Ingelman-Sundberg M; Molden E; Kringen MK
• Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2021;22(15):8221

  CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid Overload

  Harjumaki R; Pridgeon CS; Ingelman-Sundberg M
• Article: SCIENCE TRANSLATIONAL MEDICINE. 2021;13(603):eabf3637

  Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data

  van der Lee M; Allard WG; Vossen RHAM; Baak-Pablo RF; Menafra R; Deiman BALM; Deenen MJ; Neven P; Johansson I; Gastaldello S; Ingelman-Sundberg M; Guchelaar H-J; Swen JJ; Anvar SY
• Article: DRUG METABOLISM AND DISPOSITION. 2021;49(7):DMD-AR-2020-000340-508

  Primary Human Hepatocyte Spheroids as an In Vitro Tool for Investigating Drug Compounds with Low Hepatic Clearance

  Riede J; Wollmann BM; Molden E; Ingelman-Sundberg M
• Review: JAMA PSYCHIATRY. 2021;78(3):270-280

  Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure A Systematic Review and Meta-analysis

  Milosavljevic F; Bukvic N; Pavlovic Z; Miljevic C; Pesic V; Molden E; Ingelman-Sundberg M; Leucht S; Jukic MM
• Article: SCHIZOPHRENIA RESEARCH. 2021;228:590-596

  Rates of complete nonadherence among atypical antipsychotic drugs: A study using blood samples from 13,217 outpatients with psychotic disorders

  Smith RL; Tveito M; Kylleso L; Jukic MM; Ingelman-Sundberg M; Andreassen OA; Molden E
• Review: ARCHIVES OF TOXICOLOGY. 2021;95(1):11-25

  Transcriptional and post-transcriptional regulation of the pregnane X receptor: a rationale for interindividual variability in drug metabolism

  Smutny T; Hyrsova L; Braeuning A; Ingelman-Sundberg M; Pavek P
• Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2020;108(4):844-855

  Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three-Dimensional Spheroid Cultures of Primary Human Hepatocytes

  Hendriks DFG; Vorrink SU; Smutny T; Sim SC; Nordling A; Ullah S; Kumondai M; Jones BC; Johansson I; Andersson TB; Lauschke VM; Ingelman-Sundberg M
• Article: ADVANCED SCIENCE. 2020;7(15):2000248

  A 3D Cell Culture Model Identifies Wnt/β-Catenin Mediated Inhibition of p53 as a Critical Step during Human Hepatocyte Regeneration

  Oliva-Vilarnau N; Vorrink SU; Ingelman-Sundberg M; Lauschke VM
• Article: CELLS. 2020;9(4):E964-964

  Human Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis

  Hurrell T; Kastrinou-Lampou V; Fardellas A; Hendriks DFG; Nordling A; Johansson I; Baze A; Parmentier C; Richert L; Ingelman-Sundberg M
• Review: PHARMACOLOGY & THERAPEUTICS. 2019;197:122-152

  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity

  Lauschke VM; Zhou Y; Ingelman-Sundberg M
• Article: LANCET PSYCHIATRY. 2019;6(5):418-426

  Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study

  Jukic MM; Smith RL; Haslemo T; Molden E; Ingelman-Sundberg M
• Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2019;116(1):217-226

  AMP-activated protein kinase activation and NADPH oxidase inhibition by inorganic nitrate and nitrite prevent liver steatosis

  Cordero-Herrera I; Kozyra M; Zhuge Z; Haworth SM; Moretti C; Peleli M; Caldeira-Dias M; Jahandideh A; Han H; Cruz JDC; Kleschyov AL; Montenegro MF; Ingelman-Sundberg M; Weitzberg E; Lundberg JO; Carlstrom M
• Article: SCIENTIFIC REPORTS. 2018;8(1):14297

  Human hepatic 3D spheroids as a model for steatosis and insulin resistance

  Kozyra M; Johansson I; Nordling A; Ullah S; Lauschke VM; Ingelman-Sundberg M
• Article: GENETICS IN MEDICINE. 2018;20(6):622-629

  Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics

  Santos M; Niemi M; Hiratsuka M; Kumondai M; Ingelman-Sundberg M; Lauschke VM; Rodriguez-Antona C
• Article: HUMAN GENOMICS. 2018;12(1):26

  Integrating rare genetic variants into pharmacogenetic drug response predictions

  Ingelman-Sundberg M; Mkrtchian S; Zhou Y; Lauschke VM
• Article: AMERICAN JOURNAL OF PSYCHIATRY. 2018;175(5):463-470

  Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients

  Jukic MM; Haslemo T; Molden E; Ingelman-Sundberg M
• Review: ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY. 2018;58:161-185

  Pharmacoepigenetics and Toxicoepigenetics: Novel Mechanistic Insights and Therapeutic Opportunities

  Lauschke VM; Barragan I; Ingelman-Sundberg M
• Article: MOLECULAR PSYCHIATRY. 2017;22(8):1155-1163

  Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment

  Jukic MM; Opel N; Stroem J; Carrillo-Roa T; Miksys S; Novalen M; Renblom A; Sim SC; Penas-Lledo EM; Courtet P; Llerena A; Baune BT; de Quervain DJ; Papassotiropoulos A; Tyndale RF; Binder EB; Dannlowski U; Ingelman-Sundberg M
• Article: DRUG METABOLISM AND DISPOSITION. 2017;45(4):419-429

  Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell-Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive In Vitro Systems for Drug-Induced Liver Injury

  Bell CC; Lauschke VM; Vorrink SU; Palmgren H; Duffin R; Andersson TB; Ingelman-Sundberg M
• Article: HEPATOLOGY. 2016;64(5):1743-1756

  Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation

  Lauschke VM; Vorrink SU; Moro SML; Rezayee F; Nordling A; Hendriks DFG; Bell CC; Sison-Young R; Park BK; Goldring CE; Ellis E; Johansson I; Mkrtchian S; Andersson TB; Ingelman-Sundberg M
• Article: SCIENTIFIC REPORTS. 2016;6:35434

  Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability

  Hendriks DFG; Puigvert LF; Messner S; Mortiz W; Ingelman-Sundberg M
• Article: NUCLEIC ACIDS RESEARCH. 2016;44(14):6756-6769

  Single base resolution analysis of 5-hydroxymethylcytosine in 188 human genes: implications for hepatic gene expression

  Ivanov M; Kals M; Lauschke V; Barragan I; Ewels P; Kaller M; Axelsson T; Lehtio J; Milani L; Ingelman-Sundberg M
• Article: SCIENTIFIC REPORTS. 2016;6:25187

  Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease

  Bell CC; Hendriks DFG; Moro SML; Ellis E; Walsh J; Renblom A; Puigvert LF; Dankers ACA; Jacobs F; Snoeys J; Sison-Young RL; Jenkins RE; Nordling A; Mkrtchian S; Park BK; Kitteringham NR; Goldring CEP; Lauschke VM; Ingelman-Sundberg M
• Visa fler

Medarbetare och kontakt

Gruppledare

• 

  Magnus Ingelman-Sundberg

  Professor, Senior

  Telefon +46852487735

  E-postadress magnus.ingelman-sundberg@ki.se

Alla medarbetare i gruppen

• Andrea Atanasov

  Doktorand

  E-postadress andrea.atanasov@ki.se
• 

  Magnus Ingelman-Sundberg

  Professor, Senior

  Telefon +46852487735

  E-postadress magnus.ingelman-sundberg@ki.se
• Inger Johansson

  Universitetslektor

  E-postadress inger.johansson@ki.se
• 

  Marin Jukic

  Senior Forskningsspecialist

  E-postadress marin.jukic@ki.se
• Åsa Nordling

  Laboratorieassistent

  E-postadress asa.nordling@ki.se
• Marlene Willner

  Anknuten till Forskning

  E-postadress marlene.willner@ki.se
• Sander van Riet

  Postdoktor

  E-postadress sander.van.riet@ki.se

Besöksadress

Karolinska Institutet, Biomedicum, Quarter B5, Solnavägen 9, Stockholm, 171 65, Sweden

Postadress

Karolinska Institutet, Department of Physiology and Pharmacology, Ingelman-Sundberg group - Pharmacogenetics, att: (name of recipient), Stockholm, 171 71, Sweden